ArticleMetabolites2025
The Role of Visfatin/NAMPT in the Pathogenesis of Psoriasis.
Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Role of Elafin in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2026Article
- The Potential Link and Role of Zyxin in the Pathogenesis of Psoriasis and Its Associated Comorbidities.International journal of molecular sciences · 2026Article
- Evaluation of chemerin levels in the pathogenesis of psoriasis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introdcutionPsoriasis is a complex, chronic, immunologically, inflammatory, and environmentally mediated disease which may affect not only the skin, but also nails, and joints. This dermatosis is known for hyperproliferation, parakeratosis, dysregulated differentiation of keratinocytes, lack of granular layer of the skin and impaired apoptosis of keratinocytes. Methods Fifty patients with psoriasis and twenty-eight healthy individuals were enrolled in the study. Serum samples were collected both from the psoriatic patients and patients with an inguinal hernia, who served as the control group. Visfatin levels were measured by enzyme-linked immunosorbent assay. Various proteins have been well described as key contributors to the complex pathogenesis of psoriasis.
resultsIn our study, we found that serum visfatin levels were significantly higher in the psoriatic group compared to the control group. Interestingly, we observed a positive and statistically significant correlation between serum visfatin levels and HDL-C concentrations in patients with psoriasis. DISCUSSION: An elevated HDL-C level in psoriatic serum might be a sign of a compensatory response to systemic inflammation, or a marker of metabolic dysfunction, or an early prognostic signal in disease progression. However, no significant correlations were found between visfatin levels and the Psoriasis Area and Severity Index (PASI) score.
conclusionsIn summary, our findings indicate that visfatin levels are significantly altered in the serum of patients with psoriasis compared to the control group and it could be a pivotal point of understanding the pathogenesis of psoriasis and a new way of implementing therapeutic procedures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.